BUZZ-Aptose Biosciences Inc: FDA puts cancer drug trial on hold
** Drug developer's U.S listed shares slump as much as 36 pct to a 2-year low of $3.41
** Stock, down 32 pct, was on track for its worst day in three years
** Aptose says FDA put its early-stage trial on a cancer drug on hold after a review found a malfunctioning infusion pump at a clinical site where the tests were being held
** Company expects delays in the trial but says review finding does not undermine the positive safety profile of the drug
** Up to Thursday's close, the U.S.-listed stock had fallen 10 pct this year
© Thomson Reuters 2017 All rights reserved.